331729-12-5

Upstream product

• 5292-43-3 bromoacetic acid tert-butyl ester 
• 13589-72-5 5-chloro-2-hydroxybenzonitrile 

Downstream Products

• 331728-58-6 (2S,3S,4R,5R)3-azido-5-{6-[5-chloro-2-(2-oxo-2-piperazin-1-yl-ethoxy)-benzylamino]-purin-9-yl}-4-hydroxy-tetrahydro-furan-2-carboxylic acid methylamide 
• 331728-62-2 (2R,3R,4S,5S)(2-{[9-(4-azido-3-hydroxy-5-methylcarbamoyl-tetrahydrofuran-2-yl)-9H-purin-6-ylamino]-methyl}-4-chlorophenoxy)acetic acid tert-butyl ester 
• 331728-61-1 (2R,3R,4S,5S)(2-{[9-(4-azido-3-hydroxy-5-methylcarbamoyl-tetrahydrofuran-2-yl)-9H-purin-6-ylamino]-methyl}-4-chlorophenoxy)acetic acid 

Relevant academic research and scientific papers

The synthesis of highly potent, selective, and water-soluble agonists at the human adenosine A3 receptor

Using a combination of parallel and directed synthesis, the discovery of a highly potent and selective series of adenosine A3 agonists was achieved. High aqueous solubility, required for the intended parenteral route of administration, was achi

CARBAMOYL-TYPE BENZOFURAN DERIVATIVES

The present invention provides a carbamoyl-type benzofuran derivative of the formula [1]: wherein Ring Z is a group of the formula: etc.; A is a single bond, and the like; Y is a cycloalkanediyl group, etc.; R4 and R5 are the same or different and each is an optionally substituted lower alkyl group, etc.; R1 is a halogen atom, etc.; Ring B of the formula: is an optionally substituted benzene ring; and R3 is a hydrogen atom, etc., or a pharmaceutically acceptable salt thereof, which is useful as an FXa inhibitor.

Compounds for the treatment of ischemia

A3 agonists, methods of using such A3 agonists and pharmaceutical compositions containing such A3 agonists. The A3 agonists are useful for the reduction of tissue damage resulting from tissue ischemia or hypoxia

BENZOFURAN DERIVATIVE

The present invention provides a benzofuran derivative of the formula [1]: wherein x is a group of the formula: -N="or" -CH=; Y is an optionally substituted amino group, an optionally substituted cycloalkyl group or an optionally substituted saturated heterocyclic group; A is a single bond, a carbon chain optionally having a double bond within or at the end(s) of the chain, or an oxygen atom; R1 is a hydrogen atom or a halogen atom; Ring B is an optionally substituted benzene ring; and R3 is a hydrogen atom, or a pharmaceutically acceptable salt thereof, which is useful as a medicament, especially as an activated blood coagulation factor X inhibitor.